Payment overview · 2025
General Payments
$355.47
12 reported records · 10 companies
Healthcare provider profile · identity verified
John G. Symeonides, MD
Allopathic & Osteopathic Physicians|Family Medicine · PALM COAST, FL · NPI 1063600310
Verified facts
What the public records show
CMS Open Payments records show John G. Symeonides, MD received $355.47 in general payments during 2025 across 12 reported records.
HARMONY BIOSCIENCES LLC accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $96.19 | 27.1% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $45.94 | 12.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.91 | 10.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.31 | 9.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.66 | 9.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.43 | 8.8% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $21.22 | 6.0% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.82 | 5.6% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.75 | 5.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.24 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $355.47 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $96.19 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $45.94 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.91 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $34.31 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.66 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.43 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 285 | 38 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 207 | 20 |
| Atorvastatin Calcium | Atorvastatin Calcium | 161 | 35 |
| Gabapentin | Gabapentin | 133 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 112 | 26 |
| Losartan Potassium | Losartan Potassium | 101 | 23 |
| Clonazepam | Clonazepam | 94 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 19 |
| Alprazolam | Alprazolam | 86 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 16 |
| Furosemide | Furosemide | 80 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 80 | 20 |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 78 | suppressed |
| Eliquis | Apixaban | 75 | 11 |
| Sertraline Hcl | Sertraline Hcl | 75 | 12 |
| Eszopiclone | Eszopiclone | 63 | suppressed |
| Mirtazapine | Mirtazapine | 62 | 14 |
| Tramadol Hcl | Tramadol Hcl | 60 | 16 |
| Donepezil Hcl | Donepezil Hcl | 56 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 54 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 54 | 11 |
| Famotidine | Famotidine | 53 | suppressed |
| Pregabalin | Pregabalin | 50 | suppressed |
| Omeprazole | Omeprazole | 48 | suppressed |
| Potassium Chloride | Potassium Chloride | 48 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 45 | 11 |
| Spironolactone | Spironolactone | 45 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 11 |
| Lorazepam | Lorazepam | 44 | 12 |
| Topiramate | Topiramate | 38 | suppressed |
| Meloxicam | Meloxicam | 37 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Sucralfate | Sucralfate | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Prednisone | Prednisone | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 13 |
| Atenolol | Atenolol | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Metformin Hcl | Metformin Hcl | 26 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 16 |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 11 |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Simvastatin | Simvastatin | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | suppressed |
| Ramelteon | Ramelteon | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Lisinopril | Lisinopril | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 11 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $355.47 · 12 records | HARMONY BIOSCIENCES LLC | BRIXADI, MOUNJARO, PYRUKYND, REXULTI, SUBLOCADE, The Cologuard Plus Collection Kit, UBRELVY, WAKIX, Wegovy, XYWAV, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error